Claims for Patent: 9,707,226

Summary for Patent: 9,707,226

Title:	Nasal drug products and methods of their use
Abstract:	Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided.
Inventor(s):	Keegan; Fintan (Dublin, IE), Bell; Robert Gerard (Clearwater, FL), Crystal; Roger (Santa Monica, CA), Weiss; Michael Brenner (New York, NY)
Assignee:	ADAPT PHARMA LIMITED (Dublin, IE) OPIANT PHARMACEUTICALS (Santa Monica, CA)
Application Number:	15/428,705
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,707,226
Patent Claims:	1. A method of treating opioid overdose, the method comprising: delivering a 25-200 .mu.L spray of a pharmaceutical solution from a pre-primed device into a nostril of a patient, wherein the device is adapted for nasal delivery, and wherein the pharmaceutical solution comprises about 2 mg naloxone hydrochloride or a hydrate thereof, an isotonicity agent, and between about 0.005% and about 0.015% (w/v) of benzalkonium chloride. 2. The method of claim 1, wherein the isotonicity agent is present in a concentration between about 0.2% and about 1.2% (w/v). 3. The method of claim 2, wherein the pharmaceutical solution further comprises between about 0.1% and about 0.5% (w/v) of a stabilizing agent and an amount of an acid sufficient to achieve a pH between about 3.5 and about 5.5. 4. The method of claim 3, wherein: the isotonicity agent is sodium chloride; the stabilizing agent is disodium edetate; and the acid is hydrochloric acid. 5. The method of claim 4, wherein the pharmaceutical solution comprises: about 2% (w/v) naloxone hydrochloride; about 0.74% (w/v) sodium chloride; about 0.01% (w/v) benzalkonium chloride; and about 0.2% (w/v) disodium edetate. 6. The method of claim 5, wherein the device has a single reservoir containing approximately 125 .mu.L of the pharmaceutical solution. 7. The method of claim 6, wherein approximately 100 .mu.L of the pharmaceutical solution is delivered by one actuation of the device. 8. The method of claim 7, wherein the device comprises a reservoir, a piston, and a swirl chamber. 9. The method of claim 8, wherein the volume of the reservoir is not more than about 140 .mu.L. 10. The method of claim 6, further comprising storing the device for about twelve months or less at 25.degree. C. and 60% relative humidity prior to actuating the device, wherein the device retains at least about 100% of initial naloxone hydrochloride content at actuation. 11. The method of claim 1, wherein the patient experiences a geometric mean naloxone C.sub.max not less than about 2.9 ng/mL following a single spray. 12. The method of claim 11, wherein the patient experiences a plasma naloxone concentration such that the geometric mean of area under a plasma concentration versus time curve (AUC.sub.0-.infin.) is not less than about 4.5 hr*ng/mL when time is extrapolated to infinity. 13. The method of claim 1, wherein the device comprises a plunger that houses a container closure comprising a vial comprising an opening, a cannula, and a rubber stopper, wherein the stopper is configured to occlude the opening of the vial, and wherein the cannula is configured such that the cannula can pierce the stopper when the plunger applies sufficient force to the cannula. 14. The method of claim 1, wherein the spray delivers about 2 mg of naloxone hydrochloride. 15. The method of claim 1, wherein the pre-primed device is actuatable with one hand. 16. The method of claim 1, wherein delivery time is less than about 25 seconds. 17. The method of claim 16, wherein delivery time is less than about 20 seconds. 18. The method of claim 1, wherein less than about 20% of the pharmaceutical solution leaves the nasal cavity via drainage into the nasopharynx or externally. 19. The method of claim 18, wherein less than about 10% of the pharmaceutical solution leaves the nasal cavity via drainage into the nasopharynx or externally. 20. The method of claim 19, wherein less than about 5% of the pharmaceutical solution leaves the nasal cavity via drainage into the nasopharynx or externally. 21. The method of claim 1, wherein the spray is delivered as a round spray plume with an ovality ratio less than about 2.0 when measured at 3 cm. 22. The method of claim 21, wherein the ovality ratio is less than about 1.5 when measured at 3 cm. 23. The method of claim 22, wherein the ovality ratio is less than about 1.3 when measured at 3 cm. 24. The method of claim 23, wherein the ovality ratio is less than about 1.2 when measured at 3 cm. 25. The method of claim 24, wherein the ovality ratio is less than about 1.1 when measured at 3 cm. 26. The method of claim 1, wherein the patient is an opioid overdose patient or a suspected opioid overdose patient. 27. The method of claim 26, wherein the patient exhibits one or more symptoms chosen from: respiratory depression, central nervous system depression, cardiovascular depression, altered level consciousness, miotic pupils, hypoxemia, acute lung injury, aspiration pneumonia, sedation, hypotension, unresponsiveness to stimulus, unconsciousness, stopped breathing, erratic or stopped pulse, choking or gurgling sounds, blue or purple fingernails or lips, slack or limp muscle tone, contracted pupils, and vomiting. 28. The method of claim 27, wherein the patient exhibits respiratory depression or cardiovascular depression. 29. The method of claim 28, wherein the respiratory depression is caused by the illicit use of opioids, or by an accidental misuse of. 30. The method of claim 29, wherein the patient is in a lying, supine, or recovery position. 31. The method of claim 28, wherein the patient is free from respiratory depression for at least about 1 hour following treatment comprising delivery of the therapeutically effective amount of the opioid antagonist. 32. The method of claim 31, wherein the patient is free from respiratory depression for at least about 2 hours following treatment comprising delivery of the therapeutically effective amount of the opioid antagonist. 33. The method of claim 32, wherein the patient is free from respiratory depression for at least about 4 hours following treatment comprising delivery of the therapeutically effective amount of the opioid antagonist. 34. The method of claim 33, wherein the patient is free from respiratory depression for at least about 6 hours following treatment comprising delivery of the therapeutically effective amount of the opioid antagonist. 35. The method of claim 1, wherein a single spray in the nostril yields a plasma concentration of .gtoreq.0.2 ng/mL within 2.5 minutes in said patient. 36. The method of claim 35, wherein the single spray yields a plasma concentration of .gtoreq.1 ng/mL within 5 minutes in said patient. 37. The method of claim 35, wherein the single spray yields a plasma concentration of .gtoreq.3 ng/mL within 10 minutes in said patient. 38. The method of claim 35, wherein the single spray yields a plasma concentration of .gtoreq.0.2 ng/mL within 2.5 minutes in said patient. 39. The method of claim 35, wherein the single spray yields a plasma concentration of .gtoreq.1 ng/mL within 5 minutes in said patient. 40. A mist delivered from a pre-primed device comprising droplets, wherein the droplets comprise in aggregate about 2 mg of naloxone hydrochloride or a hydrate thereof, an isotonicity agent, and between about 0.005% and about 1% (w/v) of benzalkonium chloride, and wherein no more than about 10% of the droplets have a diameter less than 10 .mu.m. 41. The mist of claim 40, wherein the isotonicity agent is present in a concentration between about 0.2% and about 1.2% (w/v). 42. The mist of claim 41, wherein the isotonicity agent is sodium chloride. 43. The mist of claim 40, wherein the mist takes the shape of a round plume with an ovality ratio less than about 2.0 at a distance of 3 cm from the pre-primed device. 44. The mist of claim 43, wherein the ovality ratio of the spray is less than about 1.5 when measured at 3 cm. 45. The mist of claim 44, wherein the ovality ratio is less than about 1.3 when measured at 3 cm. 46. The mist of claim 45, wherein the ovality ratio is less than about 1.2 when measured at 3 cm. 47. The mist of claim 46, wherein the ovality ratio is less than about 1.1 when measured at 3 cm. 48. The mist of claim 40, wherein the naloxone is at least 40% bioavailable. 49. The mist of claim 48, wherein the median droplet size is between about 30 .mu.m and about 100 .mu.m. 50. The mist of claim 49, wherein approximately 50% of droplets have a diameter between about 30 .mu.m and about 70 .mu.m. 51. The mist of claim 50, wherein approximately 90% of droplets have a diameter less than about 100 .mu.m. 52. The mist of claim 51, wherein no more than approximately 2% of droplets have a diameter less than about 10 .mu.m. 53. The mist of claim 40, further comprising a stabilizing agent and an acid. 54. The mist of claim 53, wherein the stabilizing agent is disodium edetate and the acid is hydrochloric acid. 55. The mist of claim 54, the mist comprises per 100 .mu.L of aqueous solution: about 2 mg naloxone hydrochloride; about 0.74 mg NaCl; about 0.01 mg benzalkonium chloride; about 0.2 mg disodium edetate; and hydrochloric acid sufficient to achieve a pH of 3.5-5.5. 56. The mist of claim 40, wherein no more than approximately 5% of droplets have a diameter less than about 10 .mu.m. 57. The mist of claim 43, wherein the mist is delivered from a spray nozzle of a pre-primed device, and wherein no more than about 10% of the droplets have a diameter less than 10 .mu.m when the spray is measured by laser diffraction with beams measuring at both 3 cm and 6 cm from the spray nozzle. 58. The mist of claim 57, wherein the isotonicity agent is present in a concentration between about 0.2% and about 1.2% (w/v). 59. The mist of claim 57, wherein the isotonicity agent is sodium chloride. 60. The mist of claim 57, wherein the naloxone is at least 40% bioavailable. 61. The mist of claim 60, wherein the median droplet size is between about 30 .mu.m and about 100 .mu.m. 62. The mist of claim 61, wherein approximately 50% of droplets have a diameter between about 30 .mu.m and about 70 .mu.m. 63. The mist of claim 62, wherein approximately 90% of droplets have a diameter less than about 100 .mu.m. 64. The mist of claim 63, wherein no more than approximately 2% of droplets have a diameter less than about 10 .mu.m. 65. A method of treating narcotic-induced respiratory depression, the method comprising: delivering a 25-200 .mu.L spray of a pharmaceutical solution from a pre-primed device into a nostril of a patient, wherein the device is adapted for nasal delivery, and wherein the pharmaceutical solution comprises about 2 mg naloxone hydrochloride or a hydrate thereof, an isotonicity agent, and between about 0.005% and about 1% (w/v) of benzalkonium chloride. 66. The method of claim 65, wherein the isotonicity agent is present in a concentration between about 0.2% and about 1.2% (w/v). 67. The method of claim 66, wherein the pharmaceutical solution further comprises between about 0.1% and about 0.5% (w/v) of a stabilizing agent. 68. The method of claim 67, wherein the pharmaceutical solution further comprises an amount of an acid sufficient to achieve a pH between about 3.5 and about 5.5. 69. The method of claim 68, wherein: the isotonicity agent is sodium chloride; the stabilizing agent is disodium edetate; and the acid is hydrochloric acid. 70. The method of claim 65, wherein the plasma concentration versus time curve of naloxone in the patient has a t.sub.max of less than 30 minutes. 71. The method of claim 65, wherein the device comprises a plunger that houses a container closure comprising a vial comprising an opening, a cannula, and a rubber stopper, wherein the stopper is configured to occlude the opening of the vial, and wherein the cannula is configured such that the cannula can pierce the stopper when the plunger applies sufficient force to the cannula. 72. The method of claim 65, wherein the spray delivers about 2 mg of naloxone hydrochloride. 73. The method of claim 65, wherein the pre-primed device is actuatable with one hand. 74. The method of claim 73, wherein the pre-primed device has a single reservoir containing approximately 125 .mu.L of the pharmaceutical solution. 75. The method of claim 74, wherein approximately 100 .mu.L of the pharmaceutical solution is delivered by one actuation of the device. 76. The method of claim 75, wherein the volume of the reservoir is not more than about 140 .mu.L. 77. The method of claim 65, wherein delivery time is less than about 25 seconds. 78. The method of claim 77, wherein delivery time is less than about 20 seconds. 79. The method of claim 65, wherein less than about 20% of the pharmaceutical solution leaves the nasal cavity via drainage into the nasopharynx or externally. 80. The method of claim 79, wherein less than about 10% of the pharmaceutical solution leaves the nasal cavity via drainage into the nasopharynx or externally. 81. The method of claim 80, wherein less than about 5% of the pharmaceutical solution leaves the nasal cavity via drainage into the nasopharynx or externally. 82. The method of claim 65, wherein the patient is an opioid overdose patient or a suspected opioid overdose patient. 83. The method of claim 82, wherein the patient exhibits one or more symptoms chosen from: respiratory depression, central nervous system depression, cardiovascular depression, altered level consciousness, miotic pupils, hypoxemia, acute lung injury, aspiration pneumonia, sedation, hypotension, unresponsiveness to stimulus, unconsciousness, stopped breathing, erratic or stopped pulse, choking or gurgling sounds, blue or purple fingernails or lips, slack or limp muscle tone, contracted pupils, and vomiting. 84. The method of claim 83, wherein the patient exhibits respiratory depression or cardiovascular depression. 85. The method of claim 84, wherein the respiratory depression is caused by the illicit use of opioids, or by an accidental misuse of opioids. 86. The method of claim 84, wherein the patient is free from respiratory depression for at least about 1 hour following treatment comprising delivery of the therapeutically effective amount of the opioid antagonist. 87. The method of claim 86, wherein the patient is free from respiratory depression for at least about 2 hours following treatment comprising delivery of the therapeutically effective amount of the opioid antagonist. 88. The method of claim 87, wherein the patient is free from respiratory depression for at least about 4 hours following treatment comprising delivery of the therapeutically effective amount of the opioid antagonist. 89. The method of claim 88, wherein the patient is free from respiratory depression for at least about 6 hours following treatment comprising delivery of the therapeutically effective amount of the opioid antagonist. 90. The method of claim 89, wherein the patient is in a lying, supine, or recovery position. 91. The method of claim 65, wherein a single spray in the nostril yields a plasma concentration of .gtoreq.0.2 ng/mL within 2.5 minutes in said patient. 92. The method of claim 91, wherein the single spray yields a plasma concentration of .gtoreq.1 ng/mL within 5 minutes in said patient. 93. The method of claim 91, wherein the single actuation spray a plasma concentration of .gtoreq.3 ng/mL within 10 minutes in said patient. 94. The method of claim 91, wherein the single spray yields a plasma concentration of .gtoreq.0.2 ng/mL within 2.5 minutes in said patient. 95. The method of claim 91, wherein the single spray yields a plasma concentration of .gtoreq.1 ng/mL within 5 minutes in said patient. 96. A method of treating narcotic-induced respiratory depression, the method comprising: delivering a 25-200 .mu.L spray of a pharmaceutical solution from a pre-primed device into a nostril of a patient in need thereof in a manner that delivers the pharmaceutical solution in a round spray plume with an ovality ratio less than about 2.0 when measured at 3 cm from the pre-primed device, wherein the device is adapted for nasal delivery, wherein the spray comprises about 2 mg naloxone hydrochloride or a hydrate thereof, an isotonicity agent, and between about 0.005% and about 0.015% (w/v) of benzalkonium chloride, and wherein the patient experiences a geometric mean naloxone C.sub.max not less than about 2.9 ng/mL following a single spray. 97. The method of claim 96, wherein the ovality ratio is less than about 1.5 when measured at 3 cm from the pre-primed device. 98. The method of claim 97, wherein the ovality ratio is less than about 1.5 when measured at 3 cm. 99. The method of claim 98, wherein the ovality ratio is less than about 1.3 when measured at 3 cm. 100. The method of claim 99, wherein the ovality ratio is less than about 1.2 when measured at 3 cm. 101. The method of claim 100, wherein the ovality ratio is less than about 1.1 when measured at 3 cm.